Shaily Engineering Plastics Soars with 132% Profit Surge and UBS ‘Buy’ Rating
Shaily Engineering Plastics Limited has seen a sharp rise in investor interest after reporting strong financial results. The company’s net profit surged by nearly 132 percent year-on-year in Q2 FY26, while revenue from operations grew by around 34 percent over the same period. Analysts at UBS have now initiated coverage with a ‘buy’ rating, setting a target price of Rs. 4,000 per share—suggesting a potential upside of over 60 percent from current levels.
The company’s stock closed at Rs. 2,499 on the BSE, marking a modest gain of around 1 percent for the day. Over the past year, however, shares have delivered multibagger returns of more than 129 percent, with an additional 2 percent increase in the last month alone. With a market capitalisation of Rs. 11,484 crores, Shaily Engineering Plastics has positioned itself as a key player in specialised medical device technologies.
Shaily Engineering Plastics now trades at a valuation that reflects both its rapid growth and future prospects. The stock’s recent performance, combined with UBS’s bullish outlook, points to continued momentum in the coming quarters. Investors will likely watch for developments in the healthcare division and any partnerships tied to the GLP-1 generic device market.
